197 related articles for article (PubMed ID: 15491745)
1. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
Nativ O; Dalal E; Laufer M; Sabo E; Aronson M
Urology; 2004 Oct; 64(4):845-8. PubMed ID: 15491745
[TBL] [Abstract][Full Text] [Related]
2. Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Laufer M; Ramalingam S; Schoenberg MP; Haisfield-Wolf ME; Zuhowski EG; Trueheart IN; Eisenberger MA; Nativ O; Egorin MJ
J Clin Oncol; 2003 Feb; 21(4):697-703. PubMed ID: 12586808
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
Serretta V; Galuffo A; Pavone C; Allegro R; Pavone-MacAluso M
Urology; 2005 Jan; 65(1):65-9. PubMed ID: 15667865
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine in bladder cancer.
El Karak F; Flechon A
Expert Opin Pharmacother; 2007 Dec; 8(18):3251-6. PubMed ID: 18035967
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer.
Brocks CP; Büttner H; Böhle A
J Urol; 2005 Sep; 174(3):1115-8. PubMed ID: 16094076
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
Horinaga M; Fukuyama R; Iida M; Yanaihara H; Nakahira Y; Nonaka S; Deguchi N; Asakura H
Urology; 2010 Nov; 76(5):1267.e1-6. PubMed ID: 21056277
[TBL] [Abstract][Full Text] [Related]
7. Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.
Mattioli F; Curotto A; Manfredi V; Gosmar M; Garbero C; Ambruosi C; Carmignani G; Martelli A
Anticancer Res; 2005; 25(3c):2493-6. PubMed ID: 16080482
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
Gårdmark T; Carringer M; Beckman E; Malmström PU;
Urology; 2005 Sep; 66(3):527-30. PubMed ID: 16140071
[TBL] [Abstract][Full Text] [Related]
9. Intravesical gemcitabine in recurrent superficial bladder carcinoma: preliminary results on ablative efficacy and tolerability.
Campodonico F; Canepa G; Capponi G; Bozzo L; Maffezzini M
Anticancer Res; 2005; 25(3c):2381-4. PubMed ID: 16080464
[TBL] [Abstract][Full Text] [Related]
10. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Shelley MD; Jones G; Cleves A; Wilt TJ; Mason MD; Kynaston HG
BJU Int; 2012 Feb; 109(4):496-505. PubMed ID: 22313502
[TBL] [Abstract][Full Text] [Related]
11. Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).
Gontero P; Casetta G; Maso G; Sogni F; Pretti G; Zitella A; Frea B; Tizzani A
Eur Urol; 2004 Sep; 46(3):339-43. PubMed ID: 15306105
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
Campodonico F; Maffezzini M
Urology; 2005 Nov; 66(5):1141-2; author reply 1142. PubMed ID: 16286156
[No Abstract] [Full Text] [Related]
13. Intravesicle gemcitabine in management of BCG refractory superficial TCC of urinary bladder-our experience.
Mohanty NK; Nayak RL; Vasudeva P; Arora RP
Urol Oncol; 2008; 26(6):616-9. PubMed ID: 18367121
[TBL] [Abstract][Full Text] [Related]
14. Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Palou J; Carcas A; Segarra J; Duque B; Salvador J; Garcia-Ribas I; Villavicencio H
J Urol; 2004 Aug; 172(2):485-8. PubMed ID: 15247710
[TBL] [Abstract][Full Text] [Related]
15. Intravesical therapy for superficial cancer: need for more options.
Crawford ED
J Clin Oncol; 2002 Aug; 20(15):3185-6. PubMed ID: 12149286
[No Abstract] [Full Text] [Related]
16. [Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
Wang H; Liu Z; Wang ZP; Li FY; Zhao Y; Chen GP; Li DC
Zhonghua Zhong Liu Za Zhi; 2013 Jun; 35(6):412-7. PubMed ID: 24119899
[TBL] [Abstract][Full Text] [Related]
17. Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
Gontero P; Marini L; Frea B
BJU Int; 2005 Nov; 96(7):970-6. PubMed ID: 16225511
[No Abstract] [Full Text] [Related]
18. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Dalbagni G; Russo P; Sheinfeld J; Mazumdar M; Tong W; Rabbani F; Donat MS; Herr HW; Sogani P; dePalma D; Bajorin D
J Clin Oncol; 2002 Aug; 20(15):3193-8. PubMed ID: 12149290
[TBL] [Abstract][Full Text] [Related]
19. Intravesical gemcitabine for non-muscle invasive bladder cancer.
Jones G; Cleves A; Wilt TJ; Mason M; Kynaston HG; Shelley M
Cochrane Database Syst Rev; 2012 Jan; 1():CD009294. PubMed ID: 22259002
[TBL] [Abstract][Full Text] [Related]
20. Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
Karavana SY; Şenyiğit ZA; Çalışkan Ç; Sevin G; Özdemir Dİ; Erzurumlu Y; Şen S; Baloğlu E
Drug Des Devel Ther; 2018; 12():1959-1975. PubMed ID: 29997433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
